U87 CAR-T in Patients With Advanced Head and Neck Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2027

Conditions

Nasopharynx CancerHead and Neck Cancer

Interventions

DRUG

U87 autologous CAR T-cell

Treatment with U87 chimeric antigen receptor T-cell infusion.

Trial Locations (1)

RECRUITING

Eye ENT Hospital of Fudan University, Shanghai

All Listed Sponsors

lead

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

INDUSTRY